Latest News

Metformin may hinder exercise benefits, impacting blood vessel function and insulin control, raising concerns for diabetes management during physical activity.

At 3 and 9 months, inclisiran reduced low-density lipoprotein cholesterol in patients intolerant to statins or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors at rates comparable to those in placebo-controlled trials.

The Latest Kaiser Family Foundation Employer Health Benefits Survey Has Unsurprising but Consequential Findings

Integrating a pharmacist into multidisciplinary settings allowed for more thorough LDL-C lowering in unique settings.

Pharmacists’ expertise is vital to AI’s safe integration into medication management. A growing array of resources and training support pharmacists’ engagement with this new technology.

Researchers unveil a pharmacist-led intervention to enhance hypoglycemia management in older adults with type 2 diabetes, improving patient outcomes.

The FDA lifts the black box warning on hormone replacement therapy, empowering women with new options for managing menopause symptoms.

Recent analysis reveals no significant link between maternal acetaminophen use and increased autism or ADHD risk, challenging previous health claims.

Inclisiran significantly enhances LDL-C goal attainment in post-acute coronary syndrome patients, improving lipid management outcomes.

New data from AHA 2025 demonstrate the benefits of pharmacist-led hypertension management in reducing hemoglobin A1c (HbA1c) and blood pressure in minority patients with type 2 diabetes.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.